Pharming Group studies show rhC11nH inhibitor brings rapid relief to angioedema patients

By Angela McDaniels

Seattle, Nov. 17 -Pharming Group NV said results from phase 1 and phase 2 trials show that patients with hereditary angioedema treated with recombinant human C1 inhibitor (rhC11nH) begin to show relief within 15 minutes to two hours and show minimal symptoms within 12 hours.

None of the patients treated with the inhibitor showed any related serious adverse events, allergic reactions or antibody responses to study medication, nor did any patient experience a relapse of the initial angioedema attack, the company said.

The results were included in a recent edition of the Journal of Allergy and Clinical Immunology and presented at several meetings, including the CHAES Annual General Meeting and Conference in Montréal, the AAEE Meeting in Rome and the ACAAI Annual Meeting in Anaheim, Calif.

Hereditary angioedema is a human genetic disorder characterized by acute attacks of painful swelling of soft tissues, including regions of the skin, the intestine and the mouth and throat, the company said.

Sufferers have an average of seven acute attacks per year, lasting up to five days each.

Pharming Group is based in Leiden, the Netherlands, and develops protein therapeutics for unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.